Viracta Therapeutics (VIRX) Competitors $0.02 -0.01 (-16.67%) As of 03/13/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VIRX vs. KZIA, ADIL, PRTG, APM, SNOA, CPHI, VRAX, CERO, SONN, and SPRCShould you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Kazia Therapeutics (KZIA), Adial Pharmaceuticals (ADIL), Portage Biotech (PRTG), Aptorum Group (APM), Sonoma Pharmaceuticals (SNOA), China Pharma (CPHI), Virax Biolabs Group (VRAX), CERo Therapeutics (CERO), Sonnet BioTherapeutics (SONN), and SciSparc (SPRC). These companies are all part of the "pharmaceutical products" industry. Viracta Therapeutics vs. Kazia Therapeutics Adial Pharmaceuticals Portage Biotech Aptorum Group Sonoma Pharmaceuticals China Pharma Virax Biolabs Group CERo Therapeutics Sonnet BioTherapeutics SciSparc Viracta Therapeutics (NASDAQ:VIRX) and Kazia Therapeutics (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, community ranking, analyst recommendations, profitability, earnings and media sentiment. Do insiders & institutionals believe in VIRX or KZIA? 31.4% of Viracta Therapeutics shares are held by institutional investors. Comparatively, 30.9% of Kazia Therapeutics shares are held by institutional investors. 10.7% of Viracta Therapeutics shares are held by company insiders. Comparatively, 1.0% of Kazia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is VIRX or KZIA more profitable? Kazia Therapeutics' return on equity of 0.00% beat Viracta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viracta TherapeuticsN/A -1,899.61% -114.21% Kazia Therapeutics N/A N/A N/A Do analysts rate VIRX or KZIA? Viracta Therapeutics presently has a consensus target price of $4.05, suggesting a potential upside of 16,100.00%. Kazia Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 1,097.92%. Given Viracta Therapeutics' higher possible upside, analysts plainly believe Viracta Therapeutics is more favorable than Kazia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viracta Therapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Kazia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, VIRX or KZIA? Viracta Therapeutics has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Kazia Therapeutics has a beta of 2.28, suggesting that its share price is 128% more volatile than the S&P 500. Does the MarketBeat Community believe in VIRX or KZIA? Kazia Therapeutics received 51 more outperform votes than Viracta Therapeutics when rated by MarketBeat users. However, 70.73% of users gave Viracta Therapeutics an outperform vote while only 52.98% of users gave Kazia Therapeutics an outperform vote. CompanyUnderperformOutperformViracta TherapeuticsOutperform Votes2970.73% Underperform Votes1229.27% Kazia TherapeuticsOutperform Votes8052.98% Underperform Votes7147.02% Which has better valuation & earnings, VIRX or KZIA? Kazia Therapeutics has higher revenue and earnings than Viracta Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViracta TherapeuticsN/AN/A-$51.06M-$1.10-0.02Kazia Therapeutics$2.31M2.09-$17.56MN/AN/A Does the media refer more to VIRX or KZIA? In the previous week, Kazia Therapeutics had 2 more articles in the media than Viracta Therapeutics. MarketBeat recorded 2 mentions for Kazia Therapeutics and 0 mentions for Viracta Therapeutics. Kazia Therapeutics' average media sentiment score of 1.44 beat Viracta Therapeutics' score of 0.00 indicating that Kazia Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Viracta Therapeutics Neutral Kazia Therapeutics Positive SummaryKazia Therapeutics beats Viracta Therapeutics on 9 of the 14 factors compared between the two stocks. Remove Ads Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRX vs. The Competition Export to ExcelMetricViracta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$994,000.00$6.92B$5.61B$7.93BDividend YieldN/A2.72%4.89%4.05%P/E Ratio-0.026.1123.5518.73Price / SalesN/A223.52384.51119.64Price / CashN/A65.6738.0534.64Price / Book0.086.616.814.19Net Income-$51.06M$139.99M$3.19B$246.99M7 Day PerformanceN/A-2.16%5.27%-3.16%1 Month PerformanceN/A-9.48%-1.41%-11.06%1 Year PerformanceN/A-3.25%12.83%2.19% Viracta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRXViracta Therapeutics2.2126 of 5 stars$0.03-16.7%$4.05+16,100.0%-97.4%$994,000.00N/A-0.0220Gap DownKZIAKazia Therapeutics3.6766 of 5 stars$0.95-19.5%$11.50+1,110.9%-57.2%$4.78M$2.31M0.0012Short Interest ↓ADILAdial Pharmaceuticals2.6522 of 5 stars$0.72-4.0%$8.00+1,011.1%-60.2%$4.73MN/A-0.2220Short Interest ↑Gap DownPRTGPortage Biotech0.3148 of 5 stars$4.00-10.1%N/A-64.2%$4.67MN/A-0.106Short Interest ↑News CoverageGap DownAPMAptorum Group1.7015 of 5 stars$0.90-4.3%N/A-78.9%$4.66M$430,000.000.0030Short Interest ↓Gap UpSNOASonoma Pharmaceuticals0.8759 of 5 stars$2.79+40.2%N/A+2,148.2%$4.51M$13.97M-0.69180Gap UpHigh Trading VolumeCPHIChina PharmaN/A$0.23+0.1%N/A-29.8%$4.42M$5.54M0.00250Analyst ForecastNews CoverageGap UpVRAXVirax Biolabs Group0.8455 of 5 stars$1.37-2.5%N/A+51.8%$4.41M$84,872.000.005News CoverageCEROCERo TherapeuticsN/A$1.42-3.4%N/A-99.6%$4.30MN/A0.008News CoverageGap DownSONNSonnet BioTherapeutics1.8277 of 5 stars$1.40-6.0%$20.00+1,328.6%-26.3%$4.29M$1M0.0010Short Interest ↑SPRCSciSparc0.709 of 5 stars$0.40+25.2%N/A-87.7%$4.14M$1.75M0.004Gap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies KZIA Alternatives ADIL Alternatives PRTG Alternatives APM Alternatives SNOA Alternatives CPHI Alternatives VRAX Alternatives CERO Alternatives SONN Alternatives SPRC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRX) was last updated on 3/14/2025 by MarketBeat.com Staff From Our PartnersNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump Shock to change everything Is this Trump’s next major move? Millionaire trading expert Imre Gams has found a bill that directs the Uni...Centurion Publishing | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump's 100-Day Plan Triggers Global RetaliationIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIRX Stock Alerts